Value Hunters: Look To Cerevel Therapeutics Holdings Inc (CERE)

Currently, there are 181.36M common shares owned by the public and among those 87.51M shares have been available to trade.

The company’s stock has a 5-day price change of -4.61% and -6.70% over the past three months. CERE shares are trading -6.70% year to date (YTD), with the 12-month market performance up to 22.25% higher. It has a 12-month low price of $19.59 and touched a high of $43.59 over the same period. CERE has an average intraday trading volume of 1.14 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.49%, -5.08%, and 9.74% respectively.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Institutional ownership of Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) shares accounts for 47.92% of the company’s 181.36M shares outstanding.

It has a market capitalization of $7.21B and a beta (3y monthly) value of 1.41. The earnings-per-share (ttm) stands at -$2.73. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.48% over the week and 1.67% over the month.

Earnings per share for the fiscal year are expected to increase by 1.87%, and -10.21% over the next financial year.

Looking at the support for the CERE, a number of firms have released research notes about the stock. TD Cowen stated their Market Perform rating for the stock in a research note on December 08, 2023, with the firm’s price target at $45. JP Morgan coverage for the Cerevel Therapeutics Holdings Inc (CERE) stock in a research note released on November 20, 2023 offered a Neutral rating with a price target of $25. Piper Sandler was of a view on September 28, 2023 that the stock is Overweight, while BofA Securities gave the stock Neutral rating on August 03, 2023, issuing a price target of $36- $31. Wells Fargo on their part issued Overweight rating on May 04, 2023.

Most Popular

Related Posts